Literature DB >> 7477378

A huntingtin-associated protein enriched in brain with implications for pathology.

X J Li1, S H Li, A H Sharp, F C Nucifora, G Schilling, A Lanahan, P Worley, S H Snyder, C A Ross.   

Abstract

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by an expanding polyglutamine repeat in the IT15 or huntingtin gene. Although this gene is widely expressed and is required for normal development, the pathology of HD is restricted to the brain, for reasons that remain poorly understood. The huntingtin gene product is expressed at similar levels in patients and controls, and the genetics of the disorder suggest that the expansion of the polyglutamine repeat induces a toxic gain of function, perhaps through interactions with other cellular proteins. Here we report the identification of a protein (huntingtin-associated protein (HAP)-1) that binds to huntingtin. This binding is enhanced by an expanded polyglutamine repeat, the length of which is also known to correlate with the age of disease onset. The HAP-1 protein is enriched in the brain, suggesting a possible basis for the selective brain pathology of HD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477378     DOI: 10.1038/378398a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  153 in total

1.  Analysis of the subcellular localization of huntingtin with a set of rabbit polyclonal antibodies in cultured mammalian cells of neuronal origin: comparison with the distribution of huntingtin in Huntington's disease autopsy brain.

Authors:  J C Dorsman; M A Smoor; M L Maat-Schieman; M Bout; S Siesling; S G van Duinen; J J Verschuuren; J T den Dunnen; R A Roos; G J van Ommen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 2.  Polyglutamine pathogenesis.

Authors:  C A Ross; J D Wood; G Schilling; M F Peters; F C Nucifora; J K Cooper; A H Sharp; R L Margolis; D R Borchelt
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 3.  Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin.

Authors:  A S Hackam; J G Hodgson; R Singaraja; T Zhang; L Gan; C A Gutekunst; S M Hersch; M R Hayden
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

Review 4.  The localization and interactions of huntingtin.

Authors:  A L Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

5.  Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.

Authors:  P H Reddy; V Charles; M Williams; G Miller; W O Whetsell; D A Tagle
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-06-29       Impact factor: 6.237

6.  Cellular defects and altered gene expression in PC12 cells stably expressing mutant huntingtin.

Authors:  S H Li; A L Cheng; H Li; X J Li
Journal:  J Neurosci       Date:  1999-07-01       Impact factor: 6.167

7.  Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology.

Authors:  C A Gutekunst; S H Li; H Yi; J S Mulroy; S Kuemmerle; R Jones; D Rye; R J Ferrante; S M Hersch; X J Li
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

8.  Disrupted GABAAR trafficking and synaptic inhibition in a mouse model of Huntington's disease.

Authors:  Eunice Y Yuen; Jing Wei; Ping Zhong; Zhen Yan
Journal:  Neurobiol Dis       Date:  2012-02-28       Impact factor: 5.996

Review 9.  Huntingtin in health and disease.

Authors:  Anne B Young
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

10.  The Huntington's disease mutation impairs Huntingtin's role in the transport of NF-κB from the synapse to the nucleus.

Authors:  Edoardo Marcora; Mary B Kennedy
Journal:  Hum Mol Genet       Date:  2010-08-25       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.